Haohai is a high-tech biomedical enterprise focus on the R&D, manufacturing and marketing of biomedical materials primarily made of intraocular lens (IOL), medical sodium hyaluronate, medical chitosan and medical collagen. Meanwhile, Haohai also manufactures innovative drugs such as rhEGF that primarily utilize genetic engineering technology. These products have extensive clinical application covering four major business segments including ophthalmology, medical aesthetics and wound care, orthopedics, and general surgery.
Haohai intend to expend the portfolio of innovative, competitively positioned products through market-derived product development programs focusing on products that address rapidly growing clinical needs and selective acquisition of pharmaceutical or biomedical materials companies with a focus on products that have the potential for future commercialization and market in global market.
Since 2016, through a series of mergers and acquisitions, Haohai has extended its footprint to the whole IOL industry chain as follows: Haohai accessed the production of raw materials, mastered the R&D and production process and improved the downstream sales network. Currently, Haohai has a leading position in various business areas of biomedical materials:
In 2018, Haohai was one of the largest manufacturer in domestic IOL market at about 30% in sales volume. Meanwhile，Haohai was largest manufacturer in the ophthalmic viscoelstic device market, viscosupplementation product market and anti-adhesiton product market, with market share of 46.9%, 39.7% and 48.9%, respectively. Moreover, Haohai was the second largest manufacturer in the rhEGF market accounting for 20.4% of the market share.
In the future, Haohai will continue relying upon scientific and technological innovation to create a new engine of business, and contribute to the transformation and upgrading of domestic biomedical technology.
|Full name||Shanghai Haohai Biological Technology Co.,Ltd|
|Domicile||No.5 Dongjing Road， Songjiang Industrial Zone， Shanghai, China|
|CSRC Sector||Pharmaceutical manufacturing|
|Has weighted voting rights structure?||No|
|Earnings Per Share||2.59||2.33||1.91|
|R&D expenditure as a % of operating revenue||6.12%||5.64%||5.49%|
|Total Owners' Equity||3,835.45||3,385.26||2,985.86|
|Net Cash Flows-Operating||391.29||351.26||262.61|
|Net Cash Flows-Investing||-794.64||-156.59||-1,519.37|
|Net Cash Flows-Financing||-85.33||-96.48||-58.42|
|Name||No. of Shares Held (mn)||% of Shares Held|
|Shanghai Zhanze Corporate Management Partnership Enterprise (Limited Partnership)||6.47||4.04%|
|Changxing Tonghao Investment Partnership (Limited Partnership)||3.00||1.87%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.